The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is a huge mover today! About 367,750 shares traded hands or 20.32% up from the average. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) has declined 45.27% since April 6, 2016 and is downtrending. It has underperformed by 47.23% the S&P500.
The move comes after 9 months negative chart setup for the $61.17M company. It was reported on Nov, 8 by Barchart.com. We have $2.50 PT which if reached, will make NASDAQ:DRNA worth $7.34M less.
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Ratings Coverage
Out of 4 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Dicerna Pharmaceuticals has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Chardan Capital Markets maintained Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) rating on Thursday, June 30. Chardan Capital Markets has “Neutral” rating and $4 price target. The firm earned “Outperform” rating on Tuesday, September 8 by Cowen & Co. The firm earned “Buy” rating on Thursday, June 30 by Stifel Nicolaus. The stock has “Buy” rating given by Stifel Nicolaus on Tuesday, May 10. Stifel Nicolaus maintained the stock with “Buy” rating in Monday, August 10 report. Chardan Capital Markets maintained Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) on Monday, August 15 with “Neutral” rating. The stock of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) earned “Buy” rating by Stifel Nicolaus on Wednesday, November 11.
According to Zacks Investment Research, “Dicerna Pharmaceuticals, Inc. is focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers. The company uses its proprietary RNA interference technology platform primarily in the United States and internationally. Dicerna Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts.”
Insitutional Activity: The institutional sentiment decreased to 0.76 in 2016 Q2. Its down 0.24, from 1 in 2016Q1. The ratio worsened, as 15 funds sold all Dicerna Pharmaceuticals Inc shares owned while 18 reduced positions. 11 funds bought stakes while 14 increased positions. They now own 12.70 million shares or 13.90% less from 14.75 million shares in 2016Q1.
Proshare Ltd Co accumulated 0% or 15,428 shares. Blackrock Advsrs Ltd Liability Co holds 0% or 2,670 shares in its portfolio. Millennium Management Ltd Co owns 52,693 shares or 0% of their US portfolio. Blackrock Incorporated has 3,874 shares for 0% of their US portfolio. Jane Street Gp Limited Liability Company, a New York-based fund reported 10,274 shares. Dafna Cap Ltd Liability has invested 0.28% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Oxford Asset Mngmt reported 286,413 shares or 0.04% of all its holdings. Alpine Partners Vi Limited Liability Company last reported 20,488 shares in the company. Manufacturers Life Insurance The last reported 671 shares in the company. Lmr Partners Ltd Liability Partnership accumulated 11,757 shares or 0.01% of the stock. Blackrock Fund Advsr holds 0% or 315,722 shares in its portfolio. Deutsche State Bank Ag holds 0% of its portfolio in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) for 68,918 shares. Ra Management Ltd Liability Corporation last reported 1.01% of its portfolio in the stock. Art Advsr Limited Co accumulated 0.01% or 56,763 shares. Northern Tru Corp holds 0% or 36,463 shares in its portfolio.
Another recent and important Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) news was published by Businesswire.com which published an article titled: “Dicerna Pharmaceuticals Appoints John â€œJackâ€ Green Interim Chief Financial Officer” on December 15, 2015.
DRNA Company Profile
Dicerna Pharmaceuticals, Inc., incorporated on October 24, 2006, is a ribonucleic acid (RNA) interference biopharmaceutical company. The Firm operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Firm is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Firm uses its RNAi technology platform to build a pipeline in these therapeutic areas.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.